Purpose: gp96 (grp94) is a key downstream chaperone in the endoplasmic reticulum (ER) to mediate unfolded protein response (UPR) and the pathogenesis of multiple myeloma is closely linked to dysregulated UPR. In this study, we aimed to determine the roles of gp96 in the initiation and progression of multiple myeloma in vivo and in vitro.

Experimental Design: We generated a mouse model with overexpression of XBP1s and conditional deletion of gp96 in B-cell compartment simultaneously to identify the roles of gp96 in the development of multiple myeloma in vivo. Using a short hairpin RNA (shRNA) system, we silenced gp96 in multiple human multiple myeloma cells and examined the effect of gp96 knockdown on multiple myeloma cells by cell proliferation, cell-cycle analysis, apoptosis assay, immunohistochemistry, and human myeloma xenograft model. The anticancer activity of gp96 selective inhibitor, WS13, was evaluated by apoptosis assay and MTT assay.

Results: Genetic deletion of gp96 in XBP1s-Tg mice attenuates multiple myeloma. Silencing of gp96 causes severe compromise in human multiple myeloma cell growth through inhibiting Wnt-LRP-survivin pathway. We also confirmed that knockdown of gp96 decreased human multiple myeloma growth in a murine xenograft model. The targeted gp96 inhibitor induced apoptosis and blocked multiple myeloma cell growth, but did not induce apoptosis in pre-B leukemic cells. We have demonstrated that myeloma growth is dependent on gp96 both genetically and pharmacologically.

Conclusions: gp96 is essential for multiple myeloma cell proliferation and survival, suggesting that gp96 is a novel therapeutic target for multiple myeloma. Clin Cancer Res; 19(22); 6242–51. ©2013 AACR.

Translational Relevance

Multiple myeloma is an incurable plasma cell neoplasm whose pathogenesis is closely linked to dysregulated unfolded protein response (UPR) in the endoplasmic reticulum (ER). In this study, we demonstrated that the persistence of plasma cells as well as the development of myeloma is critically dependent on gp96, a major molecular chaperone in the ER in vivo. Furthermore, our results demonstrated that gp96 knockdown causes severe compromise in human multiple myeloma cell growth through attenuating Wnt-LRP-survivin pathway. Targeting gp96 in multiple myeloma cells by a gp96-specific inhibitor also blocks proliferation and induces apoptosis. This is the first study to uncover the critical roles of gp96 in the initiation and progression of multiple myeloma, suggesting that blockade of gp96 is a novel therapeutic strategy against this disease.

As an ER chaperone, gp96 (1), also known as grp94 (2), endoplasmin (3), ERp99 (4), and HSP90b1(5), is a paralogue of HSP90 and its expression can be induced by the accumulation of misfolded proteins (6). It binds to and hydrolyzes ATP (7–9), and is the most abundant protein in the endoplasmic reticulum (ER) lumen. gp96 is a key downstream chaperone in the ER to mediate unfolded protein response (UPR; refs. 10). UPR is an evolutionally conserved mechanism to maintain protein quality control in the secretory pathway. Accumulation of misfolded proteins in the ER triggers the activation of three well-known pathways including activating transcription factor 6 (ATF6), the double-stranded RNA-activated protein kinase-like ER kinase (PERK), and the spliced form of X box binding protein 1 (XBP1s) to induce the expression of several major ER HSPs including gp96, grp78, and calreticulin to enhance protein folding machinery (11). UPR plays critical roles for plasma cell differentiation as demonstrated by lack of plasma cells in the absence of XBP1 (12–14). Moreover, gp96 is induced more than 10-fold during B-cell activation (4), and it has been shown to participate in the assembly of B-cell receptor complexes through its association with immunoglobulin-α (Igα) molecules (15). In addition to the critical roles of UPR in plasma cell differentiation, a picture has recently emerged of the roles of UPR, particularly XBP1s, in myeloma pathogenesis. XBP1s and downstream ER chaperones are consistently upregulated in myeloma cells (16). Most strikingly, transgenic expression of XBP1s in the B-cell compartment of mice results in plasma cell dyscrasia with evidence of increased monoclonal antibodies (“M-spike”), lytic bone lesions, plasmacytosis, and kidney damage (17). However, the roles of individual ER HSPs in myeloma have not been reported.

Using genetic strategies, we recently found that gp96 is an obligate master chaperone for multiple Toll-like receptors (TLR) and integrins (18–21). However, under the steady-state conditions, gp96 is not required for B-cell activation, germinal center formation, plasma cell differentiation, and class-switching or affinity maturation (19). It is unclear whether gp96 is required for plasma cell biology and for the development of myeloma during chronic ER stress conditions. In this study, we addressed the roles of gp96 in myeloma using XBP1s-transgenic mice as well as multiple human multiple myeloma (MM) cell lines. We demonstrated that gp96 is required for myeloma progression both in vitro and in vivo. Mechanistically, we found that gp96 critically controls the Wnt-LRP6-survivin pathway. Our results indicated that gp96 is a novel therapeutic target for multiple myeloma.

Mice and cell lines

B-cell–specific gp96-deficient mice and wild-type control littermates have been described (19). B-cell–specific XBP1s-transgenic and gp96-deficient mice were generated by crossing our B-cell–specific gp96-deficient mice with XBP1s transgenic mice. SCID mice were kindly provided by Jennifer Wu (Medical University of South Carolina, Charleston, SC). Mice were bred and maintained according to the established guidelines and an approved protocol by Medical University of South Carolina Institutional Animal Care and Use Committee. Human multiple myeloma cell line RPMI-8226, U266B1, MM.1S, and MM.1R were purchased from American Type Culture Collection. OPM1, JK-6L, and INA-6 were kindly provided by Yubin Kang (Medical University of South Carolina). Multiple myeloma cells were cultured in RPMI medium (Sigma-Aldrich) supplemented with 10% heat-inactivated fetal calf serum (FCS; Atlas Biologicals), 55 μmol/L 2- mercaptoethanol (2-ME, Gibco), 1 mmol/L sodium pyruvate (Gibco), 10 mmol/L HEPES (Gibco), and penicillin–streptomycin (Gibco). INA-6 cells were cultured with additional 2.5 ng/mL human interleukin (IL)-6. U266B1 cells were cultured in RPMI medium supplemented with 15% heat-inactivated FCS, 1 mmol/L sodium pyruvate (Gibco), 10 mmol/L HEPES (Gibco) and penicillin–streptomycin (Gibco). All cells were cultured in 5% CO2 incubator. Gp96-mutant and WT pre-B-cell lines were provided by Brian Seed (Harvard University, Cambridge, MA).

Reagents

Antibodies used for flow cytometry were obtained from BD Biosciences and eBioscience. Antibodies against LRP6, β-catenin, survivin, c-myc, and caspase-9 were purchased from Cell Signaling Technology, cyclin D1 was obtained from Abcam, and gp96 antibody was bought from Enzo Life Sciences, Inc. Ig levels were determined by a sandwich ELISA kit from Southern Biotechnology Associates. All other chemicals were obtained from Sigma-Aldrich and Fisher Scientific. IL-4 and IL-21 were purchased from PeproTech. WS13, a gp96-specific Hsp90 inhibitor of the purine-scaffold class (22), was synthesized as previously described (23, 24) and the structure was recently reported (25).

Flow cytometry and in vitro plasma cell differentiation

Surface staining of cells and analysis on FACSCalibur and FACSVerse (Becton-Dickinson) were done as described (18, 26). B cells were purified from spleens using CD19 magnetic beads according to the manufacturer's protocol (Miltenyi Biotec). Purified murine splenic B cells were labeled with carboxyfluorescein succinimidyl ester (CFSE), and then stimulated with anti-μ antibody, agonistic CD40 antibody, and IL-21 for 3 days. This was followed by flow cytometric analysis of expression levels of cell surface CD138 by dividing cells.

Viral vectors and transduction

Human gp96 and surivin short hairpin RNA (shRNA) lentiviral vectors as well as control vector were purchased from Open Biosystems. Survivin retroviral vector and empty vector control were obtained from Origene Technologies. Cells were seeded in a 12-well plate and spin-infected with recombinant virus (3,000 rpm, 32°C, 90 minutes) in a desktop centrifuge as reported (26).

Protein extraction and Western blot analysis

Protein extraction and immunoblot were performed as described previously (20). Briefly, cells were washed three times with ice-cold PBS and lysed in radioimmunoprecipitation assay lysis buffer (0.01 mol/L sodium phosphate, pH 7.2, 150 mmol/L NaCl, 2 mmol/L EDTA, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 2 mmol/L AEBSF, 130 mmol/L bestatin, 14 mmol/L E-64, 0.3 mmol/L aprotinin, and 1 mmol/L leupeptin). Total cell lysates was resolved on denaturing and reducing 10% to 12% SDS-PAGE, and the proteins were transferred from the gel onto Immobilon-P membranes. The membrane was blocked with 5% nonfat milk in PBS and then incubated with different antibodies, followed by incubation with horseradish peroxidase (HRP)–conjugated secondary antibody. Protein bands were visualized by using enhanced chemiluminescent substrate (Pierce) or clarity enhanced chemiluminescence (ECL) substrate (Bio-Rad).

Cell growth and proliferation assays

Cell growth was assessed through the Trypan blue dye exclusion method and MTT cell viability assay according to the manufacturer's instruction. Cells were seeded at 1 × 105 cells/mL in 96-well plates. The cells were treated with 5 μmol/L gp96-specific inhibitor WS13 or vehicle control and incubated in 5% CO2 incubator at 37°C for three time points (0, 24, and 72 hours). Plates were read at 570 nm by using iMark microplate absorbance reader (Bio-Rad).

Cell-cycle analyses

A total of 1 × 106 cells were washed twice in cold PBS and fixed with 4 mL of ice-cold 70% ethanol at 4°C overnight. Cells were washed once with PBS and incubated with 40 μg/mL propidium iodide (PI) and 100 μg/mL RNAse for 30 minutes at 37°C in the dark. Cells were analyzed on a FACSCalibur. The percentage of cells in each phase of the cell cycle was quantitated using the FlowJo software (TreeStar).

Apoptosis assay

Apoptosis and cell death were determined by terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) staining according to the manufacturer's protocol (Trevigen) and flow cytometry analysis of Annexin V and propidium iodide using Annexin V apoptosis detection Kit (eBioscience).

Human myeloma xenograft model

Severe combined immunodeficient (SCID) mice (8–12 weeks old) were subcutaneously inoculated with 5 × 106 WT control and gp96 knockdown (KD) human myeloma RPMI-8226 cells, respectively. Tumor growth was monitored every week using digital calipers to measure both the longitudinal (a, mm) and transverse (b, mm) diameters. Tumor area (a × b, mm2) was plotted. Mice were also monitored for the following general health indicators: overall behavior, feeding, neuromuscular tone, body weight, and appearance of fur, etc. At the endpoint (8 weeks after tumor inoculation), the primary tumor was also excised and weighed after the mice were sacrificed. Tumor tissues were fixed in 4% formalin or frozen in optimum cutting temperature medium.

Immunohistochemistry

Cryosections of fixed xenograft tumor tissues (5 μm thick) were treated with citrate antigen retrieval for 20 minutes at 95°C, allowed to cool, permeabilized with −20°C methanol for 5 minutes, and exposed to 0.3% hydrogen peroxide for 5 minutes before blocking and incubation with primary antibody (Survivin, 1:800; Cell Signaling Technology) for 1 hour at room temperature. Slides were washed and incubated with secondary antibody (Peroxidase rabbit IgG Vectastain ABC Kit; Vector Lab) and developed with DAB substrate kit (Vector Labs). Slides were counterstained with hematoxylin before visualization on Zeiss Axio microscope.

Immunofluorescence

Cryosections of xenograft tumor tissues (5 μm thick) were fixed with 4% paraformaldehyde, permeabilized with cold methanol, blocked and stained with gp96 antibody (9G10), and costained with Alexa Fluor 488–conjugated mouse anti-HLA-ABC (BD Biosciences). Images of sections were taken under a fluorescent microscope (Zeiss) and analyzed by AxioVision 4.4 software (Carl Zeiss Micro Imaging).

Microarray analysis

Raw cDNA microarray data of myeloma samples and their corresponding clinical parameters were downloaded from Oncomine database (27). The most specific probe for gp96 was used to represent gene expression levels. Unpaired, two-tailed Student t test was used for comparison of gp96 expression.

Statistical analysis

Error bars represent the SD or the SEM. Student t test and ANOVA were used for statistical analysis. Values of P value less than 0.05 were considered to represent statistically significant differences.

Genetic deletion of gp96 in XBP1s-Tg mice attenuates myeloma

Using CD19cre-mediated deletion of gp96, we previously found that gp96 is dispensable for Ig synthesis, Ig assembly, B-cell differentiation, plasma cell development, and Ig class-switching.(19) It is unclear, however, if gp96 plays important roles in antibody production and myeloma progression during chronic ER stress. To answer this question, we generated B-cell–specific XBP1s-Tg and gp96 knockout (KO) mice (named TKO mice) by crossing B-cell–specific gp96 knockout mice with XBP1s-Tg mice; the latter spontaneously develop multiple myeloma after reaching 40 weeks of age (17). The constitutive expression of XBP1s created a scenario of chronic unresolving ER stress. As expected, without transgenic expression of XBP1s, gp96 deletion does not negatively affect plasma cell number or the level of serum antibodies (Fig. 1; ref. 19). Strikingly, we found that plasma cells (B220−/lowCD138+) were significantly reduced in number in both the bone marrow and the spleen of the TKO mice when gp96 was deleted in XBP1s transgenic mouse (Fig. 1A and B). To directly examine the plasma cell differentiation in TKO mice, we stimulated CFSE–labeled splenic B cells from WT, knockout, Tg, and TKO mice with IL-4 alone or the combination of IL-4, anti-μ antibody, agonistic CD40 antibody and IL-21 for 3 days (28). We found that TKO B cells differentiated to plasma cells as efficiently as WT, knockout, or XBP1s Tg B cells based on CD138 expression (Fig. 1C). These data indicated that the reduction of plasma cells in TKO mice is not due to inefficient plasma cell differentiation. Consistent with the reduced plasma cell number, we also found significant reduction of Ig level (both IgG1 and IgM) in TKO mice (Fig. 2A and B), along with significant reduction of γ globulin on serum protein electrophoresis (Fig. 2C and D) and decreased Ig deposition in the glomeruli (Fig. 2E). These results suggest that gp96 is required for myeloma progression during chronic ER stress.

Figure 1.

Gp96 is required for the maintenance but not the differentiation of plasma cells in XBP1s-Tg mice. A, representative FACS plots of B220CD138+ plasma cells in the bone marrow of four types of age/gender-matched mice (WT-wild type mice; KO-CD19cregp96flox/flox mice; Tg-B-cell–specific XBP1s-Tg mice; TKO-B-cell–specific gp96 knockout and XBP1s-Tg mice). Number represents % of boxed cells over total number of cells analyzed. B, quantification of plasma cells in both spleen and bone marrow of four types of mice. The reduction of plasma cells in TKO mice is statistically significant (n = 5 per group; *, P < 0.05, t test). Error bars indicate SEM. C, in vitro differentiation of plasma cells from TKO B cells is not impaired. Splenic B cells were purified with CD19 microbeads, labeled with CFSE, followed by stimulation with either IL-4 alone (top row) or IL-4 in combination with anti-μ antibody, agonistic CD40 antibody and IL21 (bottom row). Three days later, plasma cells were defined by CD138 expression and CFSE dilution. Number represents percentage of cells in each quandrant.

Figure 1.

Gp96 is required for the maintenance but not the differentiation of plasma cells in XBP1s-Tg mice. A, representative FACS plots of B220CD138+ plasma cells in the bone marrow of four types of age/gender-matched mice (WT-wild type mice; KO-CD19cregp96flox/flox mice; Tg-B-cell–specific XBP1s-Tg mice; TKO-B-cell–specific gp96 knockout and XBP1s-Tg mice). Number represents % of boxed cells over total number of cells analyzed. B, quantification of plasma cells in both spleen and bone marrow of four types of mice. The reduction of plasma cells in TKO mice is statistically significant (n = 5 per group; *, P < 0.05, t test). Error bars indicate SEM. C, in vitro differentiation of plasma cells from TKO B cells is not impaired. Splenic B cells were purified with CD19 microbeads, labeled with CFSE, followed by stimulation with either IL-4 alone (top row) or IL-4 in combination with anti-μ antibody, agonistic CD40 antibody and IL21 (bottom row). Three days later, plasma cells were defined by CD138 expression and CFSE dilution. Number represents percentage of cells in each quandrant.

Close modal
Figure 2.

Development of myeloma in XBP1s-Tg mice was blocked in the absence of gp96. A and B, sera from 5 to 16 weeks (n = 9; A) and 20 to 29 weeks (n = 10; B) Tg and TKO mice were collected. Total levels of IgG1 and IgM were measured by ELISA. C, serum protein electrophoresis was performed. Shown is a piece of representative data demonstrating the loss of γ globulin fraction in TKO mice. D, quantification of γ globulin fraction over the total protein in the serum. E, frozen kidney sections from 37-week-old Tg and TKO mice were analyzed for glomerular Ig deposition by immunofluorescence using anti-mouse IgG, IgM, IgA, κ, and λ Abs. Error bars indicate SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (t test).

Figure 2.

Development of myeloma in XBP1s-Tg mice was blocked in the absence of gp96. A and B, sera from 5 to 16 weeks (n = 9; A) and 20 to 29 weeks (n = 10; B) Tg and TKO mice were collected. Total levels of IgG1 and IgM were measured by ELISA. C, serum protein electrophoresis was performed. Shown is a piece of representative data demonstrating the loss of γ globulin fraction in TKO mice. D, quantification of γ globulin fraction over the total protein in the serum. E, frozen kidney sections from 37-week-old Tg and TKO mice were analyzed for glomerular Ig deposition by immunofluorescence using anti-mouse IgG, IgM, IgA, κ, and λ Abs. Error bars indicate SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (t test).

Close modal

gp96 is essential for multiple myeloma cell proliferation and survival

We next mined the Oncomine database (27) to gain a possible clue for the clinical significance of gp96 expression in myeloma. We found that gp96 expression is significantly elevated in multiple myeloma samples from relapsed patients compared with the ones at the initial diagnosis (Fig. 3A; P < 0.05). To further study the mechanism of gp96 dependency by multiple myeloma cells, we next silenced gp96 in human multiple myeloma cell lines using a gp96 shRNA lentiviral vector. We found that silencing of gp96 causes significantly compromised multiple myeloma cell growth. In comparison, a pre-B leukemic cell line, however, does not depend on gp96 for growth (Fig. 3B and C). Cell-cycle analysis of multiple myeloma cells revealed that there were significantly fewer cells in G2 phase and more cells in over-G2 phase upon gp96 knockdown (Fig. 3D). PI stain confirmed that more gp96 knockdown multiple myeloma cells undergo constitutive death (PI+ cells: 60.4% ± 6.62%) than their wild-type counterparts (PI+ cells: 35.3% ± 2.05%; Fig. 3E; P < 0.001). To further determine whether gp96 is required for human multiple myeloma cell growth in vivo, we performed xenograft model by inoculating WT and gp96KD RPMI-8226 multiple myeloma cells to SCID mice followed by monitoring tumor growth. Indeed, knockdown of gp96 significantly inhibited multiple myeloma tumor growth (Fig. 3F and G). TUNEL analysis of the xenografts tumor tissues confirmed that the gp96 knockdown multiple myeloma cells undergo massive apoptosis when compared with its wild-type counterpart (Fig. 3H and I).

Figure 3.

Gp96 is essential for multiple myeloma cell proliferation and survival. A, comparison of gp96 expression level in patients with multiple myeloma by cDNA microarray analysis. B, immunoblot analysis of gp96 and β-actin in WT and gp96 knockout pre-B leukemic cells as well as empty vector (EV) control and gp96 knockdown U266B1, RPMI-8226, OPM1, and INA-6 multiple myeloma cells. C, the growth of EV and gp96 knockdown multiple myeloma cells was assessed over 72 to 96 hours; WT and gp96 knockout pre-B leukemic cells were assessed over 72 hours. D, cell-cycle analysis of EV and gp96 knockdown RPMI-8226 cells by propidium iodide staining and flow cytometry. The fraction of cells in sub-G1, G1, S, G2, and over G2 was quantified by FlowJo and data was plotted. Error bars indicate SD. *, P < 0.05; **, P < 0.01 (t test). E, representative plots of EV control and gp96 knockdown RPMI-8226 cells were analyzed by flow cytometry for necrotic cells (PI+). F, SCID mice were challenged subcutaneously with 5 × 106 WT and gp96 knockdown RPMI-8226 cells. The kinetics of tumor growth was measured using a digital caliper. G, weight of excised tumor at the end of the experiment on week 8 (left) and the rate of tumor formation (right). Error bars indicate SEM. ***, P < 0.001 (ANOVA). H, xenograft tumors were stained for gp96 and class I molecule of human leukocyte antigen (HLA) by immunofluorescence. (scale bar: 25 μm). I, the apoptotic cells were detected by TUNEL staining in xenografted WT and gp96 knockdown multiple myeloma. (scale bar: 25 μm).

Figure 3.

Gp96 is essential for multiple myeloma cell proliferation and survival. A, comparison of gp96 expression level in patients with multiple myeloma by cDNA microarray analysis. B, immunoblot analysis of gp96 and β-actin in WT and gp96 knockout pre-B leukemic cells as well as empty vector (EV) control and gp96 knockdown U266B1, RPMI-8226, OPM1, and INA-6 multiple myeloma cells. C, the growth of EV and gp96 knockdown multiple myeloma cells was assessed over 72 to 96 hours; WT and gp96 knockout pre-B leukemic cells were assessed over 72 hours. D, cell-cycle analysis of EV and gp96 knockdown RPMI-8226 cells by propidium iodide staining and flow cytometry. The fraction of cells in sub-G1, G1, S, G2, and over G2 was quantified by FlowJo and data was plotted. Error bars indicate SD. *, P < 0.05; **, P < 0.01 (t test). E, representative plots of EV control and gp96 knockdown RPMI-8226 cells were analyzed by flow cytometry for necrotic cells (PI+). F, SCID mice were challenged subcutaneously with 5 × 106 WT and gp96 knockdown RPMI-8226 cells. The kinetics of tumor growth was measured using a digital caliper. G, weight of excised tumor at the end of the experiment on week 8 (left) and the rate of tumor formation (right). Error bars indicate SEM. ***, P < 0.001 (ANOVA). H, xenograft tumors were stained for gp96 and class I molecule of human leukocyte antigen (HLA) by immunofluorescence. (scale bar: 25 μm). I, the apoptotic cells were detected by TUNEL staining in xenografted WT and gp96 knockdown multiple myeloma. (scale bar: 25 μm).

Close modal

gp96 is required for canonical Wnt signaling by controlling LRP6 expression.

gp96 has recently been implicated in controlling cell surface expression of LRP6 (29). We also demonstrated that there is a strong interaction between LRP6 and gp96 (30). LRP6 is a coreceptor for the cell surface Wnt receptor Frizzled, and is required for canonical Wnt signaling. The Wnt/β-catenin signaling pathway is well known to modulate cell differentiation, proliferation, and apoptosis. The roles of the Wnt pathway in the pathogenesis of multiple myeloma have received increasing attention recently (31–33). To determine whether Wnt/β-catenin signaling defect is responsible for decreasing multiple myeloma cell growth in the absence of gp96, we compared the canonical Wnt signaling between empty vector (EV) control and gp96 knockdown RPMI-8226 cells by Western blot analysis. We found that the expression of LRP6 is compromised in gp96 knockdown multiple myeloma cells, consistent with the posttranslational chaperoning roles of LRP6 by gp96. Moreover, β-catenin, as well as the Wnt downstream targets, cyclin D1, and c-myc were significantly decreased in gp96 knockdown RPMI-8226 multiple myeloma cells (Fig. 4A). Furthermore, the growth defect of gp96 knockdown RPMI-8226 cells was significantly rescued by GSK3β inhibitors (TWS119 and lithium chloride; Fig. 4B), demonstrating that gp96 promotes myeloma growth via Wnt signaling.

Figure 4.

gp96 knockdown in multiple myeloma cells decreases canonical Wnt signaling, reduced expression of survivin, and causes mitotic catastrophe. A, immunoblot analysis of gp96, LRP6, β-catenin, cyclin D1, C-myc, grp78, and β-actin from EV control and gp96 knockdown RPMI-8226 cell lysates. B, EV control and gp96 knockdown RPMI-8226 cells were treated with TWS119 and lithium chloride (LiCl) and the cell growth was assessed at 72 hours. Cell number without inhibitors was set as 1. Error bars indicate SD. *, P < 0.05 (t test). C, immunoblot analysis of gp96, survivin, caspase-9, and β-actin from EV control, and gp96 knockdown RPMI-8226 cell lysates. D, xenograft multiple myeloma as in Fig. 3 was stained for survivin by immunohistochemistry. E, representative images of Hema 3 staining on EV, gp96 knockdown, gp96 knockdown, and survivin overexpression, and survivin knockdown RPMI-8226 cells. The arrows show multi-nucleation in gp96 knockdown and survivin knockdown cells. F–H, quantification of multi-nucleated cells from EV and gp96 knockdown RPMI-8226 cells (F), gp96 knockdown and overexpression of survivin on gp96 knockdown RPMI-8226 cells (G), and EV and survivin knockdown RPMI-8226 cells (H). The increase of multi-nucleated cells in gp96 knockdown and survivin knockdown cells (F and H) and the reduction of multi-nucleated cells in gp96 knockdown cells by overexpression of survivin (G) are statistically significant. Error bars indicate SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (t-test).

Figure 4.

gp96 knockdown in multiple myeloma cells decreases canonical Wnt signaling, reduced expression of survivin, and causes mitotic catastrophe. A, immunoblot analysis of gp96, LRP6, β-catenin, cyclin D1, C-myc, grp78, and β-actin from EV control and gp96 knockdown RPMI-8226 cell lysates. B, EV control and gp96 knockdown RPMI-8226 cells were treated with TWS119 and lithium chloride (LiCl) and the cell growth was assessed at 72 hours. Cell number without inhibitors was set as 1. Error bars indicate SD. *, P < 0.05 (t test). C, immunoblot analysis of gp96, survivin, caspase-9, and β-actin from EV control, and gp96 knockdown RPMI-8226 cell lysates. D, xenograft multiple myeloma as in Fig. 3 was stained for survivin by immunohistochemistry. E, representative images of Hema 3 staining on EV, gp96 knockdown, gp96 knockdown, and survivin overexpression, and survivin knockdown RPMI-8226 cells. The arrows show multi-nucleation in gp96 knockdown and survivin knockdown cells. F–H, quantification of multi-nucleated cells from EV and gp96 knockdown RPMI-8226 cells (F), gp96 knockdown and overexpression of survivin on gp96 knockdown RPMI-8226 cells (G), and EV and survivin knockdown RPMI-8226 cells (H). The increase of multi-nucleated cells in gp96 knockdown and survivin knockdown cells (F and H) and the reduction of multi-nucleated cells in gp96 knockdown cells by overexpression of survivin (G) are statistically significant. Error bars indicate SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (t-test).

Close modal

gp96 knockdown compromises expression of survivin and induces mitotic catastrophe in human multiple myeloma cells

We next studied the candidate molecules downstream of Wnt in controlling cell survival. We focused on examining the expression of survivin and caspases in gp96 knockdown multiple myeloma cells. We found that survivin levels were significantly reduced in the gp96 knockdown RPMI-8226 cells, which were associated with an increased level of cleaved caspase-9 (Fig. 4C). The reduction of nuclear survivin in gp96 knockdown cells was further confirmed by immunohistochemistry (Fig. 4D). Survivin is known to play important roles in spindle separation during mitosis (34). As expected, morphologic analysis of the gp96 knockdown multiple myeloma cells revealed a marked tendency toward multi-nucleation (Fig. 4E and F), a sign of mitotic catastrophe (35), which was phenocopied by survivin silencing (Fig. 4E and H). To further address that survivin is the key downstream target of gp96 that is responsible for our observed phenotype, we overexpressed survivin in gp96 knockdown cells. The mitotic arrest was significantly rescued (Fig. 4E and G).

Targeted gp96 inhibitor WS13 inhibits growth and induces death of myeloma cells

HSP90 inhibitors have been shown to be potent and promising anticancer agents (36, 37). Recent studies showed that pan-HSP90 inhibitors such as 17-AAG, Radicicol, and PU-H71 are potential therapeutics for treatment of multiple myeloma (38, 39). However, none of these studies specifically looked into the contribution by different members of HSP90 (cytosolic HSP90, gp96, and mitochondrial TRAP-1) in myeloma (40). We next determined if inhibiting gp96 could be therapeutically beneficial to myeloma without inhibiting cytosolic HSP90. WS13, a gp96-specific HSP90 inhibitor of the purine-scaffold class (22), was synthesized as previously described (23, 24). We treated multiple myeloma cells and pre-B leukemic cells with it. We observed that WS13 induced both apoptosis and necrosis, and inhibited growth of multiple myeloma cells, but did not induce death in pre-B leukemic cells (Fig. 5A and B). Thus, we have demonstrated that myeloma growth is dependent on gp96 both genetically and pharmacologically, strongly indicating that gp96 is a promising therapeutic target in multiple myeloma.

Figure 5.

Selective gp96 inhibitor WS13 inhibits growth of human multiple myeloma cells and induces apoptosis. A, pre-B leukemic cells, RMPI-8226, MM.1S, MM.1R, JK-6L, INA-6, OPM1, and U266B1 multiple myeloma cells, were treated with 5 μmol/L WS13 or vehicle control for 24 hours followed by flow cytometry analysis for necrotic cells (PI+ Annexin V+) or apoptotic cells (PI Annexin V+). B, pre-B leukemic cells RPMI and multiple human multiple myeloma cells were treated with 5 μmol/L WS13 or vehicle control for 24, 72, and 120 hours followed by quantification of live cells by MTT assay. Error bars indicate SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (t test).

Figure 5.

Selective gp96 inhibitor WS13 inhibits growth of human multiple myeloma cells and induces apoptosis. A, pre-B leukemic cells, RMPI-8226, MM.1S, MM.1R, JK-6L, INA-6, OPM1, and U266B1 multiple myeloma cells, were treated with 5 μmol/L WS13 or vehicle control for 24 hours followed by flow cytometry analysis for necrotic cells (PI+ Annexin V+) or apoptotic cells (PI Annexin V+). B, pre-B leukemic cells RPMI and multiple human multiple myeloma cells were treated with 5 μmol/L WS13 or vehicle control for 24, 72, and 120 hours followed by quantification of live cells by MTT assay. Error bars indicate SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (t test).

Close modal

UPR plays critical roles in plasma cell differentiation as well as in the pathogenesis of multiple myeloma. XBP1s and downstream ER chaperones are consistently upregulated in myeloma cells in patients (16), inspiring increasing efforts to develop UPR-targeted anti-multiple myeloma therapy (41–43). However, no studies have looked specifically into the roles of individual ER-resident chaperones in multiple myeloma. gp96 is a key downstream chaperone in the ER and mediates UPR, and yet its potential roles in multiple myeloma was unexplored (10). In this study, we selectively deleted gp96 in B cells in XBP1s transgenic mice which overexpress XBP1s in B cells and plasma cells and spontaneously develop multiple myeloma after reaching advanced age (17). We found that gp96 is required for maintenance of plasma cells in this model and it is a key driver for development of multiple myeloma. Moreover, we have demonstrated both genetically and pharmacologically that targeted inhibition of gp96 resulted in significant compromise in multiple myeloma cell growth and death that was mediated at least in part by the loss of canonical Wnt pathway (Figs. 1–3). It would be interesting to test the roles of gp96 in other myeloma models such as a transgenic mouse model that expresses myc transgene in a activation-induced deaminase (AID)-dependent manner (44). This is important given the limitation of XBP1s transgenic model in faithfully representing human myeloma (45).

Our study has added significantly to the emerging role of Wnt signaling in multiple myeloma (31–33). Human multiple myeloma cells appear to have hallmarks of active Wnt signaling by overexpressing β-catenin which promotes proliferation of multiple myeloma (46). Furthermore, blocking β-catenin with small-molecule inhibitors, AV-65 (33) or PKF115-584 (31, 32) specifically inhibits multiple myeloma cell proliferation. Paradoxically, higher expression of Wnt signaling inhibitor, Dickkopf1 (Dkk1) in bone marrow stromal cells can promote myeloma growth (47). Still other studies demonstrated that increasing Wnt signaling did not significantly affect the proliferation of multiple myeloma cells (48, 49). These studies suggest that Wnt signaling can play both positive and negative roles in the progression of multiple myeloma, likely due to the difference in the underlying pathogenesis. Our study has firmly linked the roles of gp96 with its ability to chaperone Wnt coreceptor LRP6. We showed that gp96 is required for multiple myeloma development in XBP1s transgenic mouse model whose underlying pathogenesis is dysregulated UPR. To illustrate the importance of cell type-selective roles of gp96, we found that silencing of gp96 causes significant compromise in the growth of multiple myeloma cells but not pre-B leukemic cells (Fig. 3). Thus, it is possible that multiple myeloma cells, with hallmarks of ER stress, are uniquely dependent on gp96. The explanation could be that multiple myeloma cells have a particularly stressed ER due to heightened production of Ig. When rate of protein synthesis is increased, UPR leads to increased level of HSPs including gp96 to accelerate protein folding. In the absence of gp96, the folding capacity of the ER in multiple myeloma cells is exceeded by chronic accumulation of misfolded proteins. In addition, loss of gp96 causes collapse of canonical Wnt signaling. Therefore, gp96 regulates multiple myeloma via both UPR and Wnt pathways. Our work thus suggests that Wnt pathway is under the regulation of UPR. The interplay between Wnt pathway and UPR in multiple myeloma deserves further study. Although speculative, it might also be fruitful to look at the combination of targeted therapy against both Wnt and UPR pathway for the treatment of multiple myeloma in the future.

Cancer cell metabolism is necessarily abnormal to accommodate the internal and external pressures which are secondary to excessive growth: nutrient insufficiency, free radical generation, and cellular machinery overloaded with accelerated DNA replication and protein production. gp96 stands at the intersection of causative and responsive in regard to such changes. Increased protein production upregulates gp96, making it an important compensatory response to malignant growth, and acting to protect the cell from ER stress. However, upregulated gp96 may also actively support enhanced growth signaling in the form of the canonical Wnt pathway, a commonly upregulated signaling cascade in cancer. Interestingly, survivin has been reported to be a target of Wnt signaling (33). Survivin is normally absent in healthy cells, appearing only during regulated passage through G2–M. Overexpression of survivin is correlated with multidrug resistance in multiple myeloma (50). Here, we have demonstrated that gp96 knockdown induces mitotic catastrophe and apoptosis in human multiple myeloma cells, which is characterized by loss of survivin and appearance of multi-nucleated cells (Fig. 4). Our data allow us to propose a model of the roles of gp96 in multiple myeloma cell survival (Fig. 6). We believe that gp96 is an especially important mediator of malignant growth due to its dual roles of absorbing the ER stress of cancer-driven protein production and also instigating further Wnt-survivin growth signaling.

Figure 6.

A model for the roles of gp96 in myeloma. gp96 is a critical chaperone for LRP6 and is therefore required for canonical Wnt signaling, leading to release of β-catenin from its destruction complex (dotted circle), accumulation of nuclear β-catenin, and upregulation of Wnt targets such as survivin. Deletion of gp96 compromises survivin expression, leading to its failure to safeguard mitotic spindles, and therefore initiation of apoptosis. The mechanism of XBP1s or other UPR sensors to induce gp96 expression in multiple myeloma cells is not depicted.

Figure 6.

A model for the roles of gp96 in myeloma. gp96 is a critical chaperone for LRP6 and is therefore required for canonical Wnt signaling, leading to release of β-catenin from its destruction complex (dotted circle), accumulation of nuclear β-catenin, and upregulation of Wnt targets such as survivin. Deletion of gp96 compromises survivin expression, leading to its failure to safeguard mitotic spindles, and therefore initiation of apoptosis. The mechanism of XBP1s or other UPR sensors to induce gp96 expression in multiple myeloma cells is not depicted.

Close modal

In summary, we have uncovered that both murine and human myeloma cells are exquisitely dependent on gp96 for growth in vivo and in vitro. Mechanistically, we have linked the roles of gp96 in promoting multiple myeloma to its function in chaperoning Wnt-LRP-survivin pathway. Thus, gp96-targeted inhibitors such as WS13 may prove to be a novel therapeutic against multiple myeloma in the future.

S.Z. Usmani has a commercial research grant from Celgene, Millennium, Onyx, honoraria from speakers' bureau from Celgene and Onyx. G. Chiosis is employed in the Board of directors (other than primary affiliation; e.g., consulting) of Samus Therapeutics and has ownership interest (including patents) in Samus Therapeutics. No potential conflicts of interest were disclosed by the other authors.

Conception and design: S. White-Gilbertson, S.Z. Usmani, Z. Li, B. Liu

Development of methodology: Y. Hua, J. Kellner, S.Z. Usmani, B. Liu

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Hua, S. White-Gilbertson, J. Kellner, S. Rachidi, G. Chiosis, R.A. DePinho, B. Liu

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Hua, S. White-Gilbertson, J. Kellner, S. Rachidi, S.Z. Usmani, Z. Li, B. Liu

Writing, review, and/or revision of the manuscript: Y. Hua, S. White-Gilbertson, J. Kellner, S.Z. Usmani, G. Chiosis, Z. Li, B. Liu

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): B. Liu

Study supervision: B. Liu

The authors thank Dr. Yusheng Zhu for assistance with the serum protein electrophoresis.

This work was supported by the South Carolina Clinical & Translational Research Institute at the Medical University of South Carolina KL2RR029880 and UL1RR029882 (to B. Liu), the American Cancer Society Institutional Research Grant from the American Cancer Society IRG-97-219-14 (to B. Liu NIH grants AI070603 and AI077283 (to Z. Li), NIH grants CA155226 and AG032969 (to G. Chiosis).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Srivastava
PK
,
DeLeo
AB
,
Old
LJ
. 
Tumor rejection antigens of chemically induced sarcomas of inbred mice
.
Proc Natl Acad Sci U S A
1986
;
83
:
3407
11
.
2.
Lee
AS
,
Delegeane
A
,
Scharff
D
. 
Highly conserved glucose-regulated protein in hamster and chicken cells: preliminary characterization of its cDNA clone
.
Proc Natl Acad Sci U S A
1981
;
78
:
4922
5
.
3.
Koch
G
,
Smith
M
,
Macer
D
,
Webster
P
,
Mortara
R
. 
Endoplasmic reticulum contains a common, abundant calcium-binding glycoprotein, endoplasmin
.
J Cell Sci
1986
;
86
:
217
32
.
4.
Lewis
MJ
,
Mazzarella
RA
,
Green
M
. 
Structure and assembly of the endoplasmic reticulum. The synthesis of three major endoplasmic reticulum proteins during lipopolysaccharide-induced differentiation of murine lymphocytes
.
J Biol Chem
1985
;
260
:
3050
7
.
5.
Chen
B
,
Piel
WH
,
Gui
L
,
Bruford
E
,
Monteiro
A
. 
The HSP90 family of genes in the human genome: insights into their divergence and evolution
.
Genomics
2005
;
86
:
627
37
.
6.
Kozutsumi
Y
,
Segal
M
,
Normington
K
,
Gething
MJ
,
Sambrook
J
. 
The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins
.
Nature
1988
;
332
:
462
4
.
7.
Li
Z
,
Srivastava
PK
. 
Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation
.
EMBO J
1993
;
12
:
3143
51
.
8.
Dollins
DE
,
Warren
JJ
,
Immormino
RM
,
Gewirth
DT
. 
Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones
.
Mol Cell
2007
;
28
:
41
56
.
9.
Frey
S
,
Leskovar
A
,
Reinstein
J
,
Buchner
J
. 
The ATPase cycle of the endoplasmic chaperone Grp94
.
J Biol Chem
2007
;
282
:
35612
20
.
10.
Yang
Y
,
Li
Z
. 
Roles of heat shock protein gp96 in the ER quality control: redundant or unique function?
Mol Cell
2005
;
20
:
173
82
.
11.
Malhotra
JD
,
Kaufman
RJ
. 
The endoplasmic reticulum and the unfolded protein response
.
Semin Cell Dev Biol
2007
;
18
:
716
31
.
12.
Reimold
AM
,
Iwakoshi
NN
,
Manis
J
,
Vallabhajosyula
P
,
Szomolanyi-Tsuda
E
,
Gravallese
EM
, et al
Plasma cell differentiation requires the transcription factor XBP-1
.
Nature
2001
;
412
:
300
7
.
13.
Iwakoshi
NN
,
Lee
AH
,
Vallabhajosyula
P
,
Otipoby
KL
,
Rajewsky
K
,
Glimcher
LH
. 
Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1
.
Nat Immunol
2003
;
4
:
321
9
.
14.
Shaffer
AL
,
Shapiro-Shelef
M
,
Iwakoshi
NN
,
Lee
AH
,
Qian
SB
,
Zhao
H
, et al
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation
.
Immunity
2004
;
21
:
81
93
.
15.
Foy
SP
,
Matsuuchi
L
. 
Association of B lymphocyte antigen receptor polypeptides with multiple chaperone proteins
.
Immunol Lett
2001
;
78
:
149
60
.
16.
Bagratuni
T
,
Wu
P
,
Gonzalez de Castro
D
,
Davenport
EL
,
Dickens
NJ
,
Walker
BA
, et al
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments
.
Blood
2010
;
116
:
250
3
.
17.
Carrasco
DR
,
Sukhdeo
K
,
Protopopova
M
,
Sinha
R
,
Enos
M
,
Carrasco
DE
, et al
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis
.
Cancer Cell
2007
;
11
:
349
60
.
18.
Yang
Y
,
Liu
B
,
Dai
J
,
Srivastava
PK
,
Zammit
DJ
,
Lefrancois
L
, et al
Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages
.
Immunity
2007
;
26
:
215
26
.
19.
Liu
B
,
Li
Z
. 
Endoplasmic reticulum HSP90b1 (gp96, grp94) optimizes B-cell function via chaperoning integrin and TLR but not immunoglobulin
.
Blood
2008
;
112
:
1223
30
.
20.
Liu
B
,
Yang
Y
,
Qiu
Z
,
Staron
M
,
Hong
F
,
Li
Y
, et al
Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substrate-specific cochaperone
.
Nat Commun
2010
;
1
:
79
.
21.
Staron
M
,
Yang
Y
,
Liu
B
,
Li
J
,
Shen
Y
,
Zuniga-Pflucker
JC
, et al
gp96, an endoplasmic reticulum master chaperone for integrins and Toll-like receptors, selectively regulates early T and B lymphopoiesis
.
Blood
2010
;
115
:
2380
90
.
22.
Taldone
T
,
Chiosis
G
. 
Purine-scaffold Hsp90 inhibitors
.
Curr Top Med Chem
2009
;
9
:
1436
46
.
23.
He
H
,
Zatorska
D
,
Kim
J
,
Aguirre
J
,
Llauger
L
,
She
Y
, et al
Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90
.
J Med Chem
2006
;
49
:
381
90
.
24.
Llauger
L
,
He
H
,
Kim
J
,
Aguirre
J
,
Rosen
N
,
Peters
U
, et al
Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90
.
J Med Chem
2005
;
48
:
2892
905
.
25.
Patel
PD
,
Yan
P
,
Seidler
PM
,
Patel
HJ
,
Sun
W
,
Yang
C
, et al
Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2
.
Nat Chem Biol
2013
.
doi: 10.1038/nchembio.1335. [Epub ahead of print.]
26.
Liu
B
,
Staron
M
,
Li
Z
. 
Murine but not human basophil undergoes cell-specific proteolysis of a major endoplasmic reticulum chaperone
.
PLoS ONE
2012
;
7
:
e39442
.
27.
Burington
B
,
Barlogie
B
,
Zhan
F
,
Crowley
J
,
Shaughnessy
JD
 Jr
. 
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma
.
Clin Cancer Res
2008
;
14
:
4821
9
.
28.
Ozaki
K
,
Spolski
R
,
Ettinger
R
,
Kim
HP
,
Wang
G
,
Qi
CF
, et al
Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6
.
J Immunol
2004
;
173
:
5361
71
.
29.
Weekes
MP
,
Antrobus
R
,
Talbot
S
,
Hor
S
,
Simecek
N
,
Smith
DL
, et al
Proteomic plasma membrane profiling reveals an essential role for gp96 in the cell surface expression of LDLR family members, including the LDL receptor and LRP6
.
J Proteome Res
2012
;
11
:
1475
84
.
30.
Liu
B
,
Staron
M
,
Hong
F
,
Wu
BX
,
Sun
S
,
Morales
C
, et al
Essential roles of grp94 in gut homeostasis via chaperoning canonical Wnt pathway
.
Proc Natl Acad Sci U S A
2013
;
110
:
6877
82
.
31.
Sukhdeo
K
,
Mani
M
,
Zhang
Y
,
Dutta
J
,
Yasui
H
,
Rooney
MD
, et al
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma
.
Proc Natl Acad Sci U S A
2007
;
104
:
7516
21
.
32.
Ashihara
E
,
Kawata
E
,
Nakagawa
Y
,
Shimazaski
C
,
Kuroda
J
,
Taniguchi
K
, et al
beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model
.
Clin Cancer Res
2009
;
15
:
2731
8
.
33.
Yao
H
,
Ashihara
E
,
Strovel
JW
,
Nakagawa
Y
,
Kuroda
J
,
Nagao
R
, et al
AV-65, a novel Wnt/beta-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model
.
Blood Cancer J
2011
;
1
:
e43
.
34.
Lamers
F
,
van der Ploeg
I
,
Schild
L
,
Ebus
ME
,
Koster
J
,
Hansen
BR
, et al
Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe
.
Endocr Relat Cancer
2011
;
18
:
657
68
.
35.
Kroemer
G
,
Galluzzi
L
,
Vandenabeele
P
,
Abrams
J
,
Alnemri
ES
,
Baehrecke
EH
, et al
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
.
Cell Death Differ
2009
;
16
:
3
11
.
36.
Cerchietti
LC
,
Lopes
EC
,
Yang
SN
,
Hatzi
K
,
Bunting
KL
,
Tsikitas
LA
, et al
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas
.
Nat Med
2009
;
15
:
1369
76
.
37.
Caldas-Lopes
E
,
Cerchietti
L
,
Ahn
JH
,
Clement
CC
,
Robles
AI
,
Rodina
A
, et al
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
.
Proc Natl Acad Sci U S A
2009
;
106
:
8368
73
.
38.
Ishii
T
,
Seike
T
,
Nakashima
T
,
Juliger
S
,
Maharaj
L
,
Soga
S
, et al
Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
.
Blood Cancer J
2012
;
2
:
e68
.
39.
Stuhmer
T
,
Iskandarov
K
,
Gao
Z
,
Bumm
T
,
Grella
E
,
Jensen
MR
, et al
Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells
.
Anticancer Res
2012
;
32
:
453
62
.
40.
Usmani
SZ
,
Bona
RD
,
Chiosis
G
,
Li
Z
. 
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
.
J Hematol Oncol
2010
;
3
:
40
.
41.
Papandreou
I
,
Denko
NC
,
Olson
M
,
Van Melckebeke
H
,
Lust
S
,
Tam
A
, et al
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma
.
Blood
2011
;
117
:
1311
4
.
42.
Mimura
N
,
Fulciniti
M
,
Gorgun
G
,
Tai
YT
,
Cirstea
D
,
Santo
L
, et al
Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma
.
Blood
2012
;
119
:
5772
81
.
43.
Ri
M
,
Tashiro
E
,
Oikawa
D
,
Shinjo
S
,
Tokuda
M
,
Yokouchi
Y
, et al
Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing
.
Blood Cancer J
2012
;
2
:
e79
.
44.
Chesi
M
,
Robbiani
DF
,
Sebag
M
,
Chng
WJ
,
Affer
M
,
Tiedemann
R
, et al
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
.
Cancer Cell
2008
;
13
:
167
80
.
45.
Kuehl
WM
. 
Modeling multiple myeloma by AID-dependent conditional activation of MYC
.
Cancer Cell
2008
;
13
:
85
7
.
46.
Derksen
PW
,
Tjin
E
,
Meijer
HP
,
Klok
MD
,
MacGillavry
HD
,
van Oers
MH
, et al
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells
.
Proc Natl Acad Sci U S A
2004
;
101
:
6122
7
.
47.
Fowler
JA
,
Mundy
GR
,
Lwin
ST
,
Edwards
CM
. 
Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1
.
Cancer Res
2012
;
72
:
2183
9
.
48.
Qiang
YW
,
Endo
Y
,
Rubin
JS
,
Rudikoff
S
. 
Wnt signaling in B-cell neoplasia
.
Oncogene
2003
;
22
:
1536
45
.
49.
Qiang
YW
,
Walsh
K
,
Yao
L
,
Kedei
N
,
Blumberg
PM
,
Rubin
JS
, et al
Wnts induce migration and invasion of myeloma plasma cells
.
Blood
2005
;
106
:
1786
93
.
50.
Tsubaki
M
,
Satou
T
,
Itoh
T
,
Imano
M
,
Komai
M
,
Nishinobo
M
, et al
Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells
.
Leuk Res
2012
;
36
:
1315
22
.